U.K.’s Midatech Develops Transbuccal Insulin Using Gold Nanoparticles
This article was originally published in The Pink Sheet Daily
The biocompatible gold nanoparticle technology being developed by the U.K. biotech can be used to carry insulin quickly to its site of action, and is also being evaluated with GLP-1 agonists and oncologics.
You may also be interested in...
Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.